Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Nexstim Plc Updates the Timeline for its Supplementary E-FIT Phase III Trial in Stroke Rehabilitation

Nexstim Oyj
Posted on: 19 May 17

Company announcement, Helsinki, 19 May 2017 at 9:00 am

Nexstim Plc (NXTMH:HEX, NXTMS:STO) (" Nexstim " or " Company "), a  medical  technology company developing and marketing pioneering navigated  non-invasive  brain stimulation systems  for both therapeutic  and diagnostic  applications, today provided a timeline update for its supplemental Phase III clinical trial in stroke rehabilitation, known as E-FIT (ELECTRIC FIELD NAVIGATED 1HZ RTMS FOR POST-STROKE MOTOR RECOVERY TRIAL).

The trial began enrolment in March of 2017.  Start-up issues at some of the enrolling sites have created a slight delay in the enrolment rate and Nexstim now expects the E-FIT trial to be completed in Q2 2018. This change in timing has no significant impact on the costs associated with the E-FIT trial. We are now encouraged by the recent rate of patient enrolment.

The E-FIT clinical trial, which is evaluating Nexstim's NBT® system, is designed to provide data to supplement the completed Phase III NICHE trial. The supplemental trial is being conducted at five clinical sites in the U.S.A. and is expected to recruit a total of 60 subjects.

NEXSTIM PLC
Martin Jamieson, Chairman and CEO

Further information is available on the website www.nexstim.com or by telephone:

Nexstim                                                             +447715163942
Martin Jamieson, Chairman and CEO martin.jamieson@nexstim.com
                                                                                                                                                      
UB Securities Oy (Certified Adviser)       +358 (0)9 2538 0246

Citigate Dewe Rogerson                         +44 (0)207 2821066
Katja Stout                                     katja.stout@citigatedr.co.uk

About Nexstim Plc
Nexstim is a medical technology company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic (NBT® system) and diagnostic (NBS system) applications. Nexstim's NBS system is the only FDA cleared and CE marked system based on navigated Transcranial Magnetic Stimulation (nTMS) for the pre-surgical mapping of the speech and motor cortices of the brain.

Based on the same technology platform, the Company has developed the Navigated Brain Therapy (NBT®) which is CE marked for the treatment of stroke, major depression and chronic neuropathic pain. The NBT® system is currently in a supplemental Phase III study, E-FIT trial, which will recruit 60 patients. The trial is expected to complete in Q2 2018, allowing Nexstim to file for FDA clearance. FDA clearance would allow Nexstim to start marketing and selling its NBT® system for stroke rehabilitation in the USA.

Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com

Nexstim Plc Updates the Timeline for its Supplementary E-FIT


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Nexstim Oyj via GlobeNewswire
HUG#2106172
GlobeNewswire
globenewswire.com

Last updated on: 20/05/2017

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.